Lipoprotein and Apolipoproteins With Metabolic Liver Diseases

Study Overview
=================
Brief Summary
-----------------
Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad

Detailed Description
-----------------
An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression. Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders

Official Title
-----------------
Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad

Conditions
-----------------
Disorders of Lipoprotein Metabolism and Other Lipidaemias

Intervention / Treatment
-----------------
* Other: lipoprotein and apolipoproteins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: above 20 years nonalcoholic fatty liver disease Non-Alcoholic Steatohepatitis Exclusion Criteria: 1. alcohonic hepatitis 2. Autoimmune liver disease 3. HIV postive -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| proposed cross-section study<br>100 subjects with NAFLD/NASH and negative anti-HCV Ab 50 subjects with HCC and negative anti-HCV Ab 50 subjects with HCC and positive for genotype-1 HCV 50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV 50 controls with all negative for NAFL, NASH and HCV | Other: lipoprotein and apolipoproteins<br>* To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases<br>|
| proposed longitudinal study<br>50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR 10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR 10 HCC patients and positive for genotype-1 HCV with SVR 10 HCC patients and positive for genotype-1 HCV without SVR 50 chronic hepatitis C but not NAFLD patients with SVR 10 chronic hepatitis C but not NAFLD patients without SVR | Other: lipoprotein and apolipoproteins<br>* To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad | Study the interplay between hepatitis C virus (HCV) and lipid metabolism(the HCV infection affects host lipid homeostasis, regarding transportation, synthesis, and catabolism.) | 2years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lipoprotein and Apolipoproteins metabolism